Results 171 to 180 of about 2,115,870 (306)

Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment

open access: yesAdvanced Science, EarlyView.
After oral administration, inodorous GLU‐BA self‐assembles into nanomicelles in aqueous environments to resist premature gastric adsorption. Upon reaching the intestine, endogenous esterases rapidly cleave the built‐in ester bonds in these nanomicelles to release BA and GLU, with GLU further metabolized by gut microbiota to gradually generate BA ...
Feifei Xin   +9 more
wiley   +1 more source

Diagnosis of Oral Cancers by Targeting VPAC Receptors: Preliminary Report. [PDF]

open access: yesAsian Pac J Cancer Prev, 2023
Nerli R   +6 more
europepmc   +1 more source

Chemotherapy‐Activated GSK3β‐DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma

open access: yesAdvanced Science, EarlyView.
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li   +11 more
wiley   +1 more source

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai   +12 more
wiley   +1 more source

Mitophagy and oral cancers. [PDF]

open access: yesNatl J Maxillofac Surg, 2022
Chowdhury RM.
europepmc   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Editorial: Incidence, mortality, and risk factors for oral cancers. [PDF]

open access: yesFront Oral Health
Schussel JL   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy